Primary Care of the Patient with Chronic Obstructive Pulmonary Disease-Part 4: Understanding the Clinical Manifestations of a Progressive Disease

American Journal of Medicine

Volumn 121, Issue 7 SUPPL. 1, 2008, Pages

  Cooper, Christopher B ^a   Dransfield, Mark ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

Chronic obstructive pulmonary disease; Comorbidity; Exacerbation; Hyperinflation; Lung volume reduction; Pharmacotherapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

AGE DISTRIBUTION; AIRWAY OBSTRUCTION; AIRWAY RESISTANCE; ANXIETY; ARTICLE; BACTERIAL INFECTION; BREATHING EXERCISE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG MEGADOSE; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HOSPITALIZATION; HUMAN; HYPERINFLATION; HYPOXEMIA; INFLUENZA VACCINATION; LUNG CANCER; LUNG RESECTION; LUNG TRANSPLANTATION; LUNG VOLUME; MALNUTRITION; MEDICAL SPECIALIST; MORBIDITY; MUSCLE DISEASE; MUSCLE EXERCISE; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PNEUMONIA; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PULMONARY REHABILITATION; SPIROMETRY; TACHYPNEA; VIRUS INFECTION; WEIGHT REDUCTION;

DISEASE PROGRESSION; HUMANS; LUNG; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 45349098226     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.04.005     Document Type: Article

References (75)

1. Fletcher C., and Peto R. The natural history of chronic airflow obstruction. BMJ 1 (1977) 1645-1648
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2006. [GOLD Website]. http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=1815 Accessed January 9, 2007
3. Celli B.R., MacNee W., and ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
4. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., Connett J.E., and LungHealth Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005) 233-239
5. Cooper C.B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 119 (2006) 21-31
6. National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348 (2003) 2059-2073
7. Foglio K., Carone M., Pagani M., Bianchi L., Jones P.W., and Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 94 (2000) 256-263
8. Roth M.D., Connett J.E., D'Armiento J.M., et al. Feasibility of retinoids for the treatment of emphysema study. Chest 130 (2006) 1334-1345
9. Weigt S.S., Abrazado M., Kleerup E.C., Tashkin D.P., and Cooper C.B. Time course and degree of hyperinflation with metronome-paced tachypnea in COPD patients. Proc Am Thorac Soc 3 (2006) A212
10. ZuWallack R., and Hedges H. Primary care of the patient with chronic obstructive pulmonary disease-part 3: pulmonary rehabilitation and related elements of comprehensive care. Am J Med 121 Suppl 7A (2008) S25-S32
11. Pitta F., Troosters T., Probst V.S., Spruit M.A., Decramer M., and Gosselink R. Characteristics of physical activities in daily life in COPD. Am J Respir Crit Care Med 171 (2005) 972-977
12. Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T., and Mishima M. Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest 128 (2005) 62-69
13. Cooper C.B., and Storer T.W. Exercise Testing and Interpretation (2001), Cambridge University Press, Cambridge, United Kingdom
14. Oga T., Nishimura K., Tsukino M., Sato S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003) 544-549
15. Myers J., Do D., Herbert W., Ribisl P., and Froelicher V.F. A nomogram to predict exercise capacity from a specific activity questionnaire and clinical data. Am J Cardiol 73 (1994) 591-596
16. Myers J., Prakash M., Froelicher V., Do D., Partington S., and Atwood J.E. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 346 (2002) 793-801
17. Porszasz J., Emtner M., Goto S., Somfay A., Whipp B.J., and Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 128 (2005) 2025-2034
18. Casaburi R., Mahler D.A., Jones P.W., et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19 (2002) 217-224
19. Donohue J.F., van Noord J.A., Bateman E.D., et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122 (2002) 47-55
20. Anzueto A., Tashkin D., Menjoge S., and Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 18 (2005) 75-81
21. Decramer M., Celli B., Tashkin D., et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 1 (2004) 303-312
22. O'Donnell D.E., Bertley J.C., Chau L.K., and Webb K.A. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 155 (1997) 109-115
23. O'Donnell D.E., Fluge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
24. Maltais F., Hamilton A., Marciniuk D., et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 128 (2005) 1168-1178
25. O'Donnell D.E., Voduc N., Fitzpatrick M., and Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24 (2004) 86-94
26. O'Donnell D.E., Sciurba F., Celli B., et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130 (2006) 647-656
27. Casaburi R., Kukafka D., Cooper C.B., Witek Jr. T.J., and Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 127 (2005) 809-817
28. Somfay A., Porszasz J., Lee S.M., and Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 18 (2001) 77-84
29. National Emphysema Treatment Trial Research Group. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 82 (2006) 431-443
30. Ries A.L., Make B.J., Lee S.M., and National Emphysema Treatment Trial Research Group. The effects of pulmonary rehabilitation in the national emphysema treatment trial. Chest 128 (2005) 3799-3809
31. Snell G.I., Holsworth L., Borrill Z.L., et al. The potential for bronchoscopic lung volume reduction using bronchial prostheses: a pilot study. Chest 124 (2003) 1073-1080
32. Hopkinson N.S., Toma T.P., Hansell D.M., et al. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 171 (2005) 453-460
33. Anthonisen N.R., Manfreda J., Warren C.P., et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
34. Pauwels R., Calverley P., Buist A.S., et al. COPD exacerbations: the importance of a standard definition. Respir Med 98 (2004) 99-107
35. Sethi S. Pathogenesis and treatment of acute exacerbations of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 26 (2005) 192-203
36. Burge S., and Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 41 (2003) 46s-53s
37. Seemungal T.A., Donaldson G.C., Bhowmik A., Jeffries D.J., and Wedzicha J.A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161 (2000) 1608-1613
38. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 164 (2001) 358-364
39. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002) 847-852
40. Donaldson G.C., Seemungal T.A., Patel I.S., et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 22 (2003) 931-936
41. Donaldson G.C., and Wedzicha J.A. COPD exacerbations. 1: Epidemiology. Thorax 61 (2006) 164-168
42. Patil S.P., Krishnan J.A., Lechtzin N., et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 163 (2003) 1180-1186
43. Roberts C.M., Barnes S., Lowe D., Pearson M.G., Clinical Effectiveness Evaluation Unit, and Royal College of Physicians and the Audit Subcommittee of the British Thoracic Society. Evidence for a link between mortality in acute COPD and hospital type and resources. Thorax 58 (2003) 947-949
44. Roberts C.M., Lowe D., Bucknall C.E., et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 57 (2002) 137-141
45. Groenewegen K.H., Schols A.M., and Wouters E.F. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124 (2003) 459-467
46. Connors Jr. A.F., Dawson N.V., Thomas C., and SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 154 (1996) 959-967
47. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 (2005) 925-931
48. Niewoehner D. The Impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 119 (2006) 38-45
49. Wilt TJ, Niewoehner D, Kim C, Kane RL, Linabery A, Tacklind J, MacDonald R, Rutks I. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Agency for Healthcare Research and Quality. AHRQ Pub No. 05-E017-1: August 2005. Accessed at: www.ahrq.gov.
50. Kardos P., Wencker M., Glaab T., and Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007) 144-149
51. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007) 775-789
52. Hanania N.A., Darken P., Horstman D., et al. The efficacy and safety of fluticasone propionate (250 μg)/salmeterol (50 μg) combined in the Diskus inhaler for the treatment of COPD. Chest 124 (2003) 834-843
53. Nichol K.L., Baken L., and Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 130 (1999) 397-403
54. Nichol K.L., Baken L., Wuorenma J., and Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 159 (1999) 2437-2442
55. Jackson L.A., Neuzil K.M., Yu O., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Eng J Med 348 (2003) 1747-1755
56. Bourbeau J., Julien M., Maltais F., et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 163 (2003) 585-591
57. Mannino D.M., Buist A.S., Petty T.L., Enright P.L., and Redd S.C. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 58 (2003) 388-393
58. Sidney S., Sorel M., Quesenberry Jr. C.P., DeLuise C., Lanes S., and Eisner M.D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 128 (2005) 2068-2075
59. Speizer F.E., Fay M.E., Dockery D.W., and Ferris Jr. B.G. Chronic obstructive pulmonary disease mortality in six US cities. Am Rev Respir Dis 140 pt 2 (1989) S49-S55
60. Sin D.D., and Man S.F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2 (2005) 8-11
61. Au D.H., Lemaitre R.N., Curtis J.R., Smith N.L., and Psaty B.M. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med 161 (2000) 827-830
62. Au D.H., Curtis J.R., Every N.R., McDonell M.B., and Fihn S.D. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest 121 (2002) 846-851
63. Gottlieb S.S., McCarter R.J., and Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998) 489-497
64. Salpeter S., Ormiston T., and Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4 (2005) CD003566
65. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 321 (2000) 199-204
66. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 (2004) 574-580
67. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases?. The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
68. Man S.F., Connett J.E., Anthonisen N.R., et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61 (2006) 849-853
69. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
70. Byers T., Barrera E., Fontham E.T., et al. A midpoint assessment of the American Cancer Society challenge goal to halve the US cancer mortality rates between the years 1990 and 2015. Cancer 107 (2006) 396-405
71. Bach P.B., Kattan M.W., Thornquist M.D., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 95 (2003) 470-478
72. Loganathan R.S., Stover D.E., Shi W., and Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 129 (2006) 1305-1312
73. Miller C.E., Jones S.F., Bailey W.C., and Dransfield M.T. Underdiagnosis of COPD in the National Lung Screening Trial. Chest 130 (2006) 280S
74. Licker M.J., Widikker I., Robert J., et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thorac Surg 81 (2006) 1830-1838
75. Birim O., Kappetein A.P., Waleboer M., et al. Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. J Thorac Cardiovasc Surg 132 (2006) 491-498